Found effective drug combination to cure COVID-19 patients: Bangladeshi doctors

Image
Press Trust of India Dhaka
Last Updated : May 17 2020 | 5:49 PM IST

A Bangladeshi medical team led by a senior doctor has claimed that their research on the combination of two widely used drugs has yielded astounding results in curing the patients with acute symptoms of the coronavirus that has created havoc worldwide and claimed the lives of over 312,000 people globally.

The claim by the Bangladeshi medical team, which includes prominent physicians from the country, comes amidst the desperate global attempts for a remedy to the deadly coronavirus.

We have got astounding results. Out of 60 COVID-19 patients, all recovered as the combination of the two drugs were applied, said Professor Dr Md Tarek Alam, the head of medicine department at private Bangladesh Medical College Hospital (BMCH).

Alam, a reputed clinician in Bangladesh, said a frequently used antiprotozoal medicine called Ivermectin in a single dose with Doxycycline, an antibiotic, yielded virtually the near-miraculous result in curing the patients with COVID-19.

My team was prescribing the two medicines only for coronavirus patients, most of them initially reporting with respiratory problems with related complaints, later to be tested COVID-19 positive, he said.

Bangladesh has so far reported 20,995 coronavirus cases. A total of 314 people have lost their lives in the country due to the disease.

Claiming that the efficacy of the drug developed by them was such that patients recovered from the virus within 4 days, he said, adding that there were no side effects of it.

We first ask them to be tested for COVID-19 and when found coronavirus positive we apply the drugs . . . they are recovering within four days".

"The repeated or second tests, in line with the procedure, reconfirmed them COVID-19 negative in all the cases under the research which found the combination to have no side effects on patients either, he said.

We are hundred per cent hopeful about the effectiveness of the combination, he said, adding they by now contacted the concerned government regulators and preparing to exhaust international procedures for acknowledgement of the drugs for the COVID-19 treatment.

Alam said his team was preparing a paper on the development of the drug for an international journal, as required for scientific review and acknowledgement.

Alam's associate Dr Rabiul Morshed said despite being a non-COVID-19 facility a huge number of patients directly and indirectly end up in BMCH, the country's

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 17 2020 | 5:48 PM IST

Next Story